Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug could help people with diabetes shed pounds

NCT ID NCT07220759

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 04, 2026 · Updated 4 times

Summary

This study tests a new medicine called cagrilintide to help people who are overweight or have obesity and type 2 diabetes lose weight. About 330 adults will receive either cagrilintide or a placebo for around 18 months. The main goals are to see how much weight they lose and how many achieve at least a 5% weight reduction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cagrilintide
What this could lead to
If successful, cagrilintide could offer a new medication option for significant weight loss in people with type 2 diabetes.
What could go wrong
This is still an investigational drug; it may not prove effective or could have side effects. The trial is not yet complete, so results are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 330 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Female or male (sex at birth). * Age 18 years or above at the time of signing the informed consent. * History of at least one self-reported unsuccessful dietary effort to lose body weight.(a\*) * Body mass index (BMI) \>= 27.0 kilogram per square meter (kg/m\^2). * Diagnosed with type 2 diabetes \>= 180 days before screening.(a\*) * Treatment with either lifestyle intervention(a\*), or: * Stable treatment (same drug(s), dose and dosing frequency) for at least 90 days before screening with 1-3 marketed oral antidiabetic drugs (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose cotransporter 2 inhibitor (SGLT2i), thiazolidinediones, Dipeptidyl peptidase-4 inhibitor (DPP-4i) or sulphonylureas (SU) as a single agent or in combination according to local practice.(a\*) * For up to 30% of participants the following concomitant medication is allowed: * Treatment for any indication with a stable dose of glucagon-like peptide-1 (GLP-1) containing medication, stable for at least 1 year before screening (a\*) and/or * Treatment with basal insulin minimum (0.25 units per kilogram per day (U/kg/day) or 20 units per day \[U/day\]) stable for at least 90 days before screening.(a\*) Key Exclusion Criteria: * Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.(a\*) * Treatment with glucagon-like peptide-1 (GLP-1) receptor agonist (RA) or GLP-1 containing medication within 180 days before screening, apart from those randomized according to inclusion criteria 7bi.(a\*) * Previous dosing of marketed or non-marketed amylin-based compounds.(a\*) (a\*) - As declared by the participant, reported in the medical records or at the investigator's discretion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight Type 2 diabetes

Contacts and locations

Locations

  • Accellacare

    Wilmington, North Carolina, 28401, United States

  • Attenborough Surgery

    Bushey, Hertfordshire, WD23 2NN, United Kingdom

  • Brunel Medical Practice

    Torquay, Devon, TQ1 4QX, United Kingdom

  • Buenos Aires Mácula

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1061AAE, Argentina

  • CICEMO- Consultorio de Investigación Clínica EMO

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1405BUB, Argentina

  • CMI Dr. Pletea Noemi SRL

    Bacau, 600154, Romania

  • Center for Diab,Obes & Metab

    Pembroke Pines, Florida, 33024, United States

  • Centre hospitalier universitaire vaudois CHUV

    Lausanne, 1011, Switzerland

  • Centricity Res New Bern Multispeciality

    New Bern, North Carolina, 28562, United States

  • Centricity Res Pointe-Claire

    Pointe-Claire, Quebec, H9R 4S3, Canada

  • Centricity Research Brampton Endocrinology

    Brampton, Ontario, L6S 0C6, Canada

  • Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli

    Buenos Aires, C1425AGC, Argentina

  • Chambliss Clinical Trials, LLC

    Montgomery, Alabama, 36106, United States

  • Chear Center LLC

    The Bronx, New York, 10455, United States

  • Chonnam National University Hospital

    Gwangju, 61469, South Korea

  • Clinica Korall S.R.L. Satu Mare

    Satu Mare, 440055, Romania

  • DIAB s.r.o.

    Rožňava, 04801, Slovakia

  • Debreceni Egyetem

    Debrecen, Hajdú-Bihar, 4032, Hungary

  • Diabet Med SRL

    Bucharest, 050913, Romania

  • Diabetes Adipositas Zentrum Zürich

    Zollikerberg, 8125, Switzerland

  • Diabmed Dr Popescu Alexandrina SRL

    Ploieşti, Prahova, 100179, Romania

  • Diex Recherche Victoriaville

    Victoriaville, Quebec, G6P 3Z8, Canada

  • EUC Klinika Praha a.s.

    Prague, 150 00, Czechia

  • East West Med Res Inst

    Honolulu, Hawaii, 96814, United States

  • G.A. Research Associates Ltd.

    Moncton, New Brunswick, E1G 1A7, Canada

  • Hamilton Medical Research Group

    Hamilton, Ontario, L8L 5G4, Canada

  • Hammersmith and Fulham Partnership Research Unit - Richford Gate Primary Care Centre

    London, W6 7HY, United Kingdom

  • Headlands Research CTR Lincoln

    Lincoln, California, 95648, United States

  • Holston Medical Group_Bristol

    Bristol, Tennessee, 37620, United States

  • IRIDIA s.r.o.

    Vrútky, 038 61, Slovakia

  • Kantonsspital Olten

    Olten, 4600, Switzerland

  • Komáromi Selye János Kórház

    Komárom, 2900, Hungary

  • Kyunghee University Medical Center

    Seoul, 130-872, South Korea

  • Lékařský dům Géčko

    České Budějovice, 370 11, Czechia

  • MediSphere Medical RC

    Evansville, Indiana, 47714, United States

  • Milan Kvapil s.r.o.

    Prague, 149 00, Czechia

  • Milestone Research

    London, Ontario, N5W 6A2, Canada

  • National Clin Res Inc.

    Richmond, Virginia, 23294, United States

  • Nemocnica akademika L. Derera, UNB

    Bratislava, 831 01, Slovakia

  • Noble Clinical Research

    Tucson, Arizona, 85704, United States

  • North Coast Medical Ltd

    Newquay, Cornwall, TR7 1RU, United Kingdom

  • Nova Scotia Hlth Halifax

    Halifax, Nova Scotia, B3H 1V7, Canada

  • OCT Research ULC (dba Okanagan Clinical Trials)

    Kelowna, British Columbia, V1Y 1Z9, Canada

  • Oak Tree Surgery

    Liskeard, Cornwall, PL14 3XA, United Kingdom

  • Opca bolnica Karlovac

    Karlovac, 47000, Croatia

  • Optimal Research Sites

    Orange City, Florida, 32763, United States

  • Pacific Clinical Studies

    Los Alamitos, California, 90720, United States

  • Palm Beach Research Center

    West Palm Beach, Florida, 33409, United States

  • Poliklinika SLAVONIJA OSIJEK

    Osijek, 31000, Croatia

  • Poliklinika Solmed

    Zagreb, 10000, Croatia

  • Pusan National University Yangsan Hospital

    Yangsan, Gyeongsangnam-do, 50612, South Korea

  • QUALICLINIC Egészségügyi Szolgáltató és Kutatásszervező Kft

    Budapest, Pest County, 1036, Hungary

  • S.C Milena Sante SRL

    Galati, 800001, Romania

  • Scripps Whittier Diabetes Inst

    La Jolla, California, 92037, United States

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Spartanburg Medical Research

    Spartanburg, South Carolina, 29303, United States

  • Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology

    Krapinske Toplice, 49217, Croatia

  • TPMG Clinical Research

    Newport News, Virginia, 23606, United States

  • The Catholic University of Korea, Seoul ST. Mary's Hospital

    Seoul, 06591, South Korea

  • The Catholic University of Korea, Yeouido ST. Mary's Hospital

    Seoul, 07345, South Korea

  • Univ of Alabama_Birmingham

    Birmingham, Alabama, 35294, United States

  • Universitätsspital Basel

    Basel, 4031, Switzerland

  • Velocity Clinical Res-Dallas

    Dallas, Texas, 75230, United States

  • Walgreens - Store 3915

    Las Vegas, Nevada, 89146, United States

  • Walgreens - Store 4442

    Kissimmee, Florida, 34746, United States

  • Wharton Medical Clinic Clinical Trials (Hamilton)

    Hamilton, Ontario, L8L 5G8, Canada

  • Óbudai Egészségügyi Centrum

    Budapest, Pest County, 1036, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.